Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases - BioSpace
Biotech startup Amplitude Therapeutics is partnering with pharma giant Eli Lilly to develop new RNA vaccine technology for infectious diseases, potentially changing how we fight global health threats.
- Amplitude Therapeutics and Eli Lilly have formed a strategic research collaboration.
- The partnership aims to develop trans-amplifying RNA (taRNA) vaccines for infectious diseases.
- Amplitude's proprietary taRNA technology will be combined with Lilly's global capabilities.
- The initial focus is on diseases with high unmet medical need.
- Lilly has options to expand the collaboration to two more targets.
Amplitude Therapeutics, a company specializing in a unique form of RNA technology called trans-amplifying RNA (taRNA), has announced a significant research collaboration with Eli Lilly and Company.
This partnership will leverage Amplitude's innovative taRNA platform, which is designed to amplify RNA molecules, potentially leading to more effective vaccines. The initial focus of their joint effort will be on developing vaccines for infectious diseases that currently have limited treatment options.
Lilly's extensive experience in drug development, manufacturing, and global distribution will be crucial in bringing these new vaccine candidates to the public if they prove successful. The agreement also includes options for Lilly to expand the collaboration to target up to two additional infectious diseases, underscoring their confidence in Amplitude's technology.
This collaboration represents a major validation for Amplitude's taRNA technology and could pave the way for next-generation vaccines against a range of challenging pathogens.
This summary is an original, AI-generated overview based on publicly available information. All rights to the original article or video remain with the source publisher.